RxDoctor Payments Data

Rene Compean, MD

Family Medicine · Laredo, TXNPI 1114942885

Payments from drug & device makers

$1,025in general payments, 2019–2025

Across 44 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$570
  • Teva Pharmaceuticals USA, Inc.$198
  • Alkermes, Inc.$93
  • Lilly USA, LLC$73
  • E.r. Squibb & Sons, L.L.C.$29
  • Lundbeck LLC$27
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$1,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,025 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$21,412
Medicare patients
31
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$22,117
TrulicityDulaglutide22$21,010
FarxigaDapagliflozin Propanediol32$19,003
JanuviaSitagliptin Phosphate30$18,611
OzempicSemaglutide12$11,357
LantusInsulin Glargine,hum.Rec.Anlog13$1,261
Desloratadine105$981
Atorvastatin Calcium366$961
Pantoprazole Sodium200$881
Metformin Hcl324$837
Pregabalin12$602
Amlodipine Besylate278$597
Misoprostol12$567
Levothyroxine Sodium129$547
Lisinopril201$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$73$21,01022 claims
AstraZenecaFarxiga$570$19,00332 claims
MerckJanuvia$13$18,61130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →